US007300670B2

(12) **United States Patent**
Venus et al.

(10) **Patent No.: US 7,300,670 B2**
(45) **Date of Patent: Nov. 27, 2007**

(54) **ORAL SUSPENSION FORMULATION**

(75) Inventors: **Danilo R. Venus**, Laguna (PH); **Eulogio C. Singh**, Rizal (PH); **Rita Josefina M. Santos**, Quezon (PH); **Ma. Joyce Bedelia B. Santos**, Mandaluyong (PH); **Kennie U. Dee**, Quezon (PH)

(73) Assignee: **Unilab Pharmatech, Ltd.**, Central Hong Kong (CN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 891 days.

(21) Appl. No.: **10/115,792**

(22) Filed: **Apr. 3, 2002**

(65) **Prior Publication Data**

US 2003/0191192 A1 Oct. 9, 2003

(51) **Int. Cl.**
A61K 9/14 (2006.01)
A61K 9/00 (2006.01)

(52) **U.S. Cl.** **424/489**; 424/400; 514/937

(58) **Field of Classification Search** 424/486, 424/400, 489; 514/937
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,607,050	A *	8/1986	Kieran et al.	514/520
4,975,465	A	12/1990	Motola et al.	514/557
5,112,604	A	5/1992	Beaurline et al.	424/490
5,272,137	A *	12/1993	Blasé et al.	514/54
5,374,659	A	12/1994	Gowan, Jr.	514/57
5,409,907	A	4/1995	Blase et al.	514/54
5,621,005	A	4/1997	Gowan, Jr.	514/557
5,658,919	A	8/1997	Ratnaraj et al.	514/269
5,712,310	A	1/1998	Koch	514/570
5,759,579	A	6/1998	Singh et al.	424/485
6,231,890	B1 *	5/2001	Naito et al.	424/489
2002/0039594	A1 *	4/2002	Unger	424/426
2003/0072800	A1 *	4/2003	Singh et al.	424/464

OTHER PUBLICATIONS

Nakhare et al. ("Prolonged release of rifampicin from multiple W/O/W emulsion," in J. Microencapsulation, 1995, vol. 12, No. 4, 409-415).*

Pages 340 and 831 of The Condensed Chemical Dictionary, Ninth edition, 1977, edited by Hawley, Gessner G.*

Page 298 of Remington's Pharmaceutical Sciences, eighteenth edition, 1990, edited by Gennaro, Alfonso R.*

Ofner, Schnaare and Schwartz, "Oral Aqueous Suspensions." Pharmaceutical Dosage Form: Disperse Systems, vol. 2, edited by Lieberman, Rieger, and Banker, First Edition, pp. 234-236.

* cited by examiner

Primary Examiner—Michael G. Hartley
Assistant Examiner—Blessing Fubara
(74) *Attorney, Agent, or Firm*—Thomas T. Aquilla

(57) **ABSTRACT**

An aqueous pharmaceutical suspension for oral administration of a drug, which suspension maintains its content uniformity for prolonged period.

4 Claims, No Drawings